Albireo Compound definition

Albireo Compound means Albireo’s proprietary compound designated by Albireo on the Effective Date as “A3309” which has the chemical structure set forth in Schedule 1.9, including, without limitation, all [***] thereof. Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Sample 1
Albireo Compound or “Elobixibat” shall mean Seller’s proprietary compound designated by Seller on the Effective Date of the License Agreement as “A3309,” which has the chemical structure set forth in Schedule 1.9 of the License Agreement, including all pharmaceutically acceptable salts, hydrates, solvates, metabolites and enantiomers thereof.
Sample 1

Examples of Albireo Compound in a sentence

  • Except as permitted by this Agreement, Ajinomoto will not exercise or otherwise exploit the Albireo Technology to commercialize the Albireo Compound and Products (i) in the Field outside of the Territory; or (ii) outside the Field.

  • Except as permitted by this Agreement, Albireo will not exercise or otherwise exploit the Ajinomoto Technology for any purpose other than to commercialize the Albireo Compound and Products in the Field outside the Territory.

  • If a Party receives a notice that a Regulatory Authority desires to conduct an inspection or audit of its or the other Party’s facility, or a facility under contract with it or the other Party, with regard to the Albireo Compound and a Product, then the Party who has received such notice shall promptly notify the other Party of such inspection or audit.

  • Neither Albireo nor its Affiliates shall, directly or indirectly, through Licensees or otherwise, commercialize the Albireo Compound and/or a Product as a pharmaceutical product to treat or prevent Liver Diseases.

  • The Parties shall use good faith efforts to execute a supply agreement (the “Supply Agreement”) and a quality agreement (the “Quality Agreement”) for the Clinical Supply within ninety (90) days after the Effective Date, which Supply Agreement and Quality Agreement shall be on terms consistent with those set forth in this Section 4.4.1, and shall contain terms and conditions customary to the supply of pharmaceutical products similar to the Albireo Compound and the Products.

  • All Albireo Compound or Product delivered pursuant to this Section 4.4.1 and/or the Supply Agreement shall conform to any applicable specifications mutually agreed upon by the Parties.

  • If (i) the Development, Commercialization or Manufacture of the Albireo Compound or a Product under this Agreement; or (ii) any development, manufacture, or commercialization of the Albireo Compound or a Product by Albireo or Licensees is alleged by a Third Party to infringe a Third Party’s patent right(s) or misappropriate a Third Party’s trade secret, the Party becoming aware of such allegation shall promptly notify the other Party thereof, in writing, reasonably detailing the claim.

  • After First Commercial Sale of a Product [***] in a country in the Territory [***], neither Ajinomoto nor any of its Affiliates shall, directly or indirectly, or in collaboration with any Third Party, license or otherwise authorize any Third Party to distribute for sale and sell commercially in such country any pharmaceutical products for the treatment of CIC or IBS-C (each such product, a “Restricted Product”), other than the Albireo Compound and Products, without complying with this Section 6.3.1; [***].

  • For the sake of clarity, neither Ajinomoto nor any of its Sublicensees or Affiliates shall conduct clinical Development activities related to the Albireo Compound or Products outside of the Territory.

  • With respect to any data, study results, and other information relating to the Albireo Compound and Products presented by Albireo to Ajinomoto prior to the Effective Date or during the Term, Albireo shall promptly notify Ajinomoto if Albireo should become aware of any material incompleteness and/or material inaccuracy of such data, study results, and other information.

Related to Albireo Compound

  • Licensed Compound means [***].

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Exempt compound means the same as defined in Rule 2.

  • Development Candidate means a Collaboration Compound designated by Biogen Idec as a Development Candidate in accordance with Section 2.6.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Compounds means any or all of the following chemicals, as the context requires:

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Licensed Product means a product, method or service in the Licensed Field of Use, the making, having made, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent.

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • Biosimilar Product means, with respect to a Licensed Product in any country, any biosimilar product sold by a Third Party not authorized by or on behalf of Celgene, its Affiliates or Sublicensees, (a) that is a biosimilar biological product, as defined in 21 USC 379j-51 (or any successor or replacement thereof), a similar biological medicinal product, as defined in Annex I to Directive 2001/83/EC (or any successor or replacement thereof), or any similar biosimilar or generic product under the Laws of any country or jurisdiction, or (b) regarding which Regulatory Approval is obtained by referencing Regulatory Data of such Licensed Product.

  • Covered Product The consumer product that You purchased concurrently with and is covered by this Agreement.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Drug Product means a specific drug in dosage form from a known source of manufacture, whether

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • GSK will have the meaning set forth in the Preamble.

  • Drug Substance means an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Clinical Studies means human clinical trials for a Licensed Product and any other tests and studies for a Licensed Product in human subjects.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.